Kyowa Kirin (KYKOF) Stock Price, News & Analysis

Company Overview

Kyowa Kirin Co., Ltd. is a Japan-based pharmaceutical company and a member of the Kirin Holdings group. The company researches, develops, manufactures and markets prescription medicines, with an emphasis on specialty therapies for conditions that often have significant unmet medical needs.

Its focus areas include oncology, immunology, nephrology, neurology and rare diseases. Kyowa Kirin’s products include Crysvita (burosumab), a treatment for certain phosphate-wasting disorders, and Poteligeo (mogamulizumab), an antibody therapy used for specific blood cancers. The company also maintains a portfolio of medicines for patients in Japan and international markets.

Kyowa Kirin traces its history to Kyowa Hakko Kogyo and adopted its current name in 2008 following the integration of Kyowa Hakko’s pharmaceutical operations with Kirin’s healthcare business. The company serves customers through operations and commercial partnerships in Japan, North America, Europe and other international markets. Its shares trade on the Tokyo Stock Exchange, while its American depositary shares are quoted over the counter in the United States under the symbol KYKOF.

Key Stats

• Today's Range: $16.30 to $16.58
• 50-Day Range: $13.90 to $16.75
• 52-Week Range: $4.20 to $17.07
• Volume: 2,308 shs
• Average Volume: 8,868 shs
• Market Capitalization: N/A
• P/E Ratio: 0.47
• Dividend Yield: 122.33%
• Price Target: N/A
• Consensus Rating: Reduce

Kyowa Kirin Stock Analysis - MarketRank™

Kyowa Kirin scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Kyowa Kirin has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Kyowa Kirin has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Kyowa Kirin is 0.47, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.40.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kyowa Kirin is 0.47, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.56.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Kyowa Kirin has a short interest ratio ("days to cover") of 999.99, which indicates bearish sentiment.

Change versus previous month

Short interest in Kyowa Kirin has recently decreased by 8.02%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Kyowa Kirin pays a meaningful dividend of 1.56%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Kyowa Kirin does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Kyowa Kirin is 58.08%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kyowa Kirin insiders have not sold or bought any company stock.

Percentage Held by Institutions

10.28% of the stock of Kyowa Kirin is held by institutions.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:KYKOF
• CIK: N/A
• Web: www.kyowakirin.co.jp
• Phone: (135) 205-7200
• Fax: N/A
• Employees: 5,161
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 0.47
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A